This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Search results
-
MedImmune Ventures
Hamermesh, Richard G.; Lane, DavidCase HBS-814023-EEntrepreneurshipRon Laufer is the new Senior Managing Director of MedImmune Ventures', the corporate venture capital arm of AstraZeneca, a leading pharmaceuticals firm. Laufer has to decide whether to pursue a high-potential, but very risky, early-stage investment. The decision Laufer will make will reflect his vision for MedImmune Ventures and more broadly the incentives he faces as a corporate venture capitalist.Starting at €8.20
-
MedImmune Ventures, Teaching Plan
Hamermesh, Richard G.; Otazo, AndrewTeaching Note HBS-814039-EEntrepreneurship"MedImmune Ventures" highlights the problems faced by corporate venture capital firms, the challenges of investing in early-stage healthcare, and the difficulty of operating in distant markets.Starting at €0.00
-
Building an Integrated Biopharma Company: Crucell (B)
Hamermesh, Richard G.; Van Der Steen, Marianne; Harmeling, Susan S.Case HBS-815086-EEntrepreneurshipThe Crucell (B) case updates events at Crucell since 2009. In September, 2009, Johnson & Johnson acquired 18% of Crucell for $400 million. This investment was part of a business development deal. Subsequently, in 2012, Johnson & Johnson acquired Crucell for $2.8 billion.Starting at €5.74
-
Building an Integrated Biopharma Company: Crucell (A)
Hamermesh, Richard G.; Van Der Steen, Marianne; Harmeling, Susan S.Case HBS-815085-EEntrepreneurshipBy 2009, Crucell had become the largest biopharma company in the Netherlands and a symbol of national pride. The case traces the evolution of the company from a University spin-off into a fully-integrated company. Crucell's success, particularly in the vaccine space, had begun to attract the attention of much larger pharmaceutical companies. While there was much appeal to working with these companies, these relationships could also challenge Cruc...Starting at €8.20
-
Building Life Science Businesses Spring Term 2017: Course Outline and Syllabus
Hamermesh, Richard G.Case HBS-815003-EEntrepreneurshipThis Course Outline and Syllabus gives an overview of the Spring 2017 class Building Life Science Businesses.Starting at €8.20
-
Building Life Science Businesses Fall Term 2013: Course Outline and Syllabus, Course Overview Note
Hamermesh, Richard G.Case HBS-814019-EEntrepreneurshipThis Course Outline and Syllabus gives an overview of the Fall 2013 class Building Life Science Businesses.Starting at €8.20
-
Shurgard Self-Storage: Expansion to Europe (Abridged)
Hamermesh, Richard G.Case HBS-810102-EEntrepreneurshipThis case is accompanied by a Video Short that can be shown in class or included in a digital coursepack. Instructors should consider the timing of making the video available to students, as it may reveal key case details. Shurgard, a U.S.-based firm that rents storage facilities to consumers and small businesses, is considering financing options for rapid expansion of its European operations. Five years after entering Europe, Shurgard Europe has...Starting at €8.20
-
Kathy Giusti and the Multiple Myeloma Research Foundation
Hamermesh, Richard G.; Margolis, Joshua D.; Preble, MatthewCase HBS-814026-EService and Operations ManagementWhat do you do when your rising professional career is cut short by an unexpected cancer diagnosis? Kathy Giusti shifted careers, built a new organization that transformed how cancer research is done, and now faces the challenge of sustaining the organization and its funding for its newest venture. Since she was first diagnosed with multiple myeloma (MM) in 1996, Giusti had led an effort to better understand and treat the disease. She had co-fou...Starting at €8.20